P glycoprotein (P-gp) and drug resistance--time for reappraisal?
作者信息
Kaye S B
出版信息
Br J Cancer. 1993 Apr;67(4):641-3. doi: 10.1038/bjc.1993.119.
Abstract
摘要
相似文献
1
P glycoprotein (P-gp) and drug resistance--time for reappraisal?P糖蛋白（P-gp）与耐药性——是时候重新评估了吗？
Br J Cancer. 1993 Apr;67(4):641-3. doi: 10.1038/bjc.1993.119.
2
Multidrug resistance due to P-glycoprotein.
Hosp Pract (Off Ed). 1990 Apr 15;25(4):67-72, 74, 77. doi: 10.1080/21548331.1990.11703935.
3
Multidrug resistance in human cancer.人类癌症中的多药耐药性。
Crit Rev Oncol Hematol. 1992;12(3):243-53. doi: 10.1016/1040-8428(92)90057-w.
4
Mechanism of multidrug resistance.多药耐药机制。
Biochim Biophys Acta. 1988 Aug 3;948(1):87-128. doi: 10.1016/0304-419x(88)90006-6.
5
Multidrug resistance: P-glycoprotein and its allies--the elusive foes.
J Natl Cancer Inst. 1989 Jun 21;81(12):910-3. doi: 10.1093/jnci/81.12.910.
6
Drug resistance and cancer.耐药性与癌症
Adv Exp Med Biol. 1993;330:287-305. doi: 10.1007/978-1-4615-2926-2_20.
7
Multidrug resistance: molecular biology and clinical relevance.
J Natl Cancer Inst. 1989 Jun 21;81(12):907-10. doi: 10.1093/jnci/81.12.907.
8
The clinical relevance of multidrug resistance.多重耐药性的临床相关性。
Cancer Invest. 1990;8(5):547-62. doi: 10.3109/07357909009012080.
9
Charles F. Kettering Prize. P-glycoprotein and resistance to anticancer drugs.
Cancer. 1992 May 15;69(10):2603-9. doi: 10.1002/1097-0142(19920515)69:10<2603::aid-cncr2820691034>3.0.co;2-e.
10
Clinical significance of P-glycoprotein in multidrug resistance malignancies.
Blood. 1993 May 1;81(9):2215-22.
引用本文的文献
1
Origin of multidrug resistance in cells with and without multidrug resistance genes: chromosome reassortments catalyzed by aneuploidy.具有和不具有多药耐药基因的细胞中多药耐药性的起源：非整倍体催化的染色体重排。
Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11283-8. doi: 10.1073/pnas.201398998. Epub 2001 Sep 11.
2
Epirubicin: a review of its intravesical use in superficial bladder cancer.表柔比星：浅表性膀胱癌膀胱内应用的综述
Drugs Aging. 1999 Oct;15(4):307-33. doi: 10.2165/00002512-199915040-00006.
3
Multidrug resistance phenotype in the RMS-GR human rhabdomyosarcoma cell line obtained after polychemotherapy.多药化疗后获得的RMS-GR人横纹肌肉瘤细胞系中的多药耐药表型。
Jpn J Cancer Res. 1999 Jul;90(7):788-93. doi: 10.1111/j.1349-7006.1999.tb00816.x.
4
A new mdr-1 encoded P-170 specific monoclonal antibody: (6/1C) on paraffin wax embedded tissue without pretreatment of sections.一种新的由多药耐药基因1（mdr-1）编码的P-170特异性单克隆抗体：（6/1C）用于未经切片预处理的石蜡包埋组织。
J Clin Pathol. 1997 Jun;50(6):465-71. doi: 10.1136/jcp.50.6.465.
5
Classical multidrug resistance in acute myeloid leukaemia.急性髓系白血病中的经典多药耐药性
Med Oncol. 1997 Mar;14(1):53-60. doi: 10.1007/BF02990947.
6
Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia.阿霉素联合SDZ PSC 833在P388和P388/DOX白血病小鼠中的分布及活性
Br J Cancer. 1996 Apr;73(7):866-71. doi: 10.1038/bjc.1996.154.
7
Inhibition of P-glycoprotein-mediated vinblastine transport across HCT-8 intestinal carcinoma monolayers by verapamil, cyclosporine A and SDZ PSC 833 in dependence on extracellular pH.维拉帕米、环孢素A和SDZ PSC 833对P-糖蛋白介导的长春碱跨HCT-8肠癌细胞单层转运的抑制作用与细胞外pH的关系
Cancer Chemother Pharmacol. 1994;34(2):125-32. doi: 10.1007/BF00685929.
8
Relative cytotoxicities of adriamycin and epirubicin in combination with lonidamine against human bladder cancer cell lines.阿霉素和表柔比星联合氯尼达明对人膀胱癌细胞系的相对细胞毒性。
Urol Res. 1995;22(6):367-72. doi: 10.1007/BF00296877.
9
Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833.用环孢菌素类似物SDZ PSC 833预处理的小鼠中阿霉素分布和毒性的变化。
Cancer Chemother Pharmacol. 1995;36(4):335-40. doi: 10.1007/BF00689051.
本文引用的文献
1
Uptake and retention of daunomycin by mouse leukemic cells as factors in drug response.
Cancer Res. 1968 May;28(5):938-41.
2
3
Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine.人类“MDR1”基因全长cDNA的表达赋予了对秋水仙碱、阿霉素和长春花碱的抗性。
Proc Natl Acad Sci U S A. 1987 May;84(9):3004-8. doi: 10.1073/pnas.84.9.3004.
4
The effect of verapamil on the pharmacokinetics of adriamycin.
Cancer Chemother Pharmacol. 1986;18(3):239-42. doi: 10.1007/BF00273394.
5
Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells.“非典型”多药耐药人类白血病细胞的药理学、分子学及细胞遗传学分析
Cancer Res. 1987 Oct 15;47(20):5455-60.
6
Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin A.改善的细胞蓄积是蒽环类药物的特征，这类药物在多药耐药细胞系中单独使用或与维拉帕米或环孢素A联合使用时仍保持高活性。
Biochem Pharmacol. 1989 Dec 15;38(24):4467-75. doi: 10.1016/0006-2952(89)90658-8.
7
Multidrug resistance: molecular biology and clinical relevance.
J Natl Cancer Inst. 1989 Jun 21;81(12):907-10. doi: 10.1093/jnci/81.12.907.
8
Reversal of drug-resistance by cyclosporin-A in a patient with acute myelocytic leukaemia.
Br J Haematol. 1990 Jun;75(2):208-11. doi: 10.1111/j.1365-2141.1990.tb02650.x.
9
MDR1 gene expression and treatment outcome in acute myeloid leukemia.
J Natl Cancer Inst. 1991 May 15;83(10):708-12. doi: 10.1093/jnci/83.10.708.
10
Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction.通过聚合酶链反应对人类肿瘤中MDR1（多药耐药）基因表达进行定量分析。
Proc Natl Acad Sci U S A. 1990 Sep;87(18):7160-4. doi: 10.1073/pnas.87.18.7160.
Zotero 插件